[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610089":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":51,"centralContacts":54,"locations":62,"responsibleParty":182,"collaborators":11,"id":184,"slug":185,"hasResults":186,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":11,"eligibilityCriteria":190,"healthyVolunteers":186,"sex":191,"minAge":192,"maxAge":11,"enrollmentInfo":193,"targetDuration":11,"studyType":196,"phases":197,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,20,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL",null,[13],"Drug: BMS-986523",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Arm C",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Arm D",[13,23],"Drug: Pembrolizumab",{"label":25,"type":10,"description":11,"interventionNames":26},"Arm E",[13,27],"Drug: Cetuximab",{"label":29,"type":10,"description":11,"interventionNames":30},"Arm F",[13,31,32],"Drug: Gemcitabine","Drug: Nab-Paclitaxel",[34,39,42,45,48],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"DRUG","BMS-986523","Specified dose on specified days",[9,15,18,21,25,29],{"type":35,"name":40,"description":37,"armGroupLabels":41,"otherNames":11},"Gemcitabine",[29],{"type":35,"name":43,"description":37,"armGroupLabels":44,"otherNames":11},"Nab-Paclitaxel",[29],{"type":35,"name":46,"description":37,"armGroupLabels":47,"otherNames":11},"Cetuximab",[25],{"type":35,"name":49,"description":37,"armGroupLabels":50,"otherNames":11},"Pembrolizumab",[21],[52],{"name":5,"affiliation":5,"role":53},"STUDY_DIRECTOR",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":11,"email":59},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":61,"role":57,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[63,81,95,109,123,139,153,169],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Johns Hopkins Hospital","RECRUITING","Baltimore","Maryland","21287","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-76.61219,39.29038,{"lat":75,"lon":74},[78],{"name":79,"role":57,"phone":80,"phoneExt":11,"email":11},"Nilofer Azad, Site 0009","410-502-2995",{"facility":82,"status":65,"city":83,"state":84,"zip":85,"country":69,"countryCode":70,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"NEXT Oncology","San Antonio","Texas","78229",{"type":72,"coordinates":87},[88,89],-98.49363,29.42412,{"lat":89,"lon":88},[92],{"name":93,"role":57,"phone":94,"phoneExt":11,"email":11},"David Sommerhalder, Site 0001","210-580-9500",{"facility":96,"status":65,"city":97,"state":98,"zip":99,"country":69,"countryCode":70,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"START Mountain Region","West Valley City","Utah","84119",{"type":72,"coordinates":101},[102,103],-112.00105,40.69161,{"lat":103,"lon":102},[106],{"name":107,"role":57,"phone":108,"phoneExt":11,"email":11},"Justin Call, Site 0007","801-907-4750",{"facility":110,"status":65,"city":111,"state":112,"zip":113,"country":69,"countryCode":70,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"NEXT Virginia","Fairfax","Virginia","22031",{"type":72,"coordinates":115},[116,117],-77.30637,38.84622,{"lat":117,"lon":116},[120],{"name":121,"role":57,"phone":122,"phoneExt":11,"email":11},"Alexander Spira, Site 0011","703-280-5390",{"facility":124,"status":65,"city":125,"state":126,"zip":127,"country":128,"countryCode":129,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"BC Cancer Vancouver","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":72,"coordinates":131},[132,133],-123.11934,49.24966,{"lat":133,"lon":132},[136],{"name":137,"role":57,"phone":138,"phoneExt":11,"email":11},"Daniel Renouf, Site 0002","6048776000Ext3297",{"facility":140,"status":65,"city":141,"state":142,"zip":143,"country":128,"countryCode":129,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9",{"type":72,"coordinates":145},[146,147],-79.39864,43.70643,{"lat":147,"lon":146},[150],{"name":151,"role":57,"phone":152,"phoneExt":11,"email":11},"Albiruni Abdul Razak, Site 0010","6479709845",{"facility":154,"status":155,"city":156,"state":157,"zip":158,"country":159,"countryCode":160,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Local Institution - 0006","NOT_YET_RECRUITING","Badalona","Barcelona [Barcelona]","08916","Spain","ES",{"type":72,"coordinates":162},[163,164],2.24741,41.45004,{"lat":164,"lon":163},[167],{"name":168,"role":57,"phone":11,"phoneExt":11,"email":11},"Site 0006",{"facility":170,"status":155,"city":171,"state":172,"zip":173,"country":159,"countryCode":160,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Local Institution - 0008","Hortaleza","Madrid","28050",{"type":72,"coordinates":175},[176,177],-3.6411,40.47444,{"lat":177,"lon":176},[180],{"name":181,"role":57,"phone":11,"phoneExt":11,"email":11},"Site 0008",{"type":183,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610089","phase-1-a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-bms-986523-alone-and-in-combination-with-anti-cancer-agents-in-participants-with-advanced-solid-malignancies-100610089",false,"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","A Phase 1\u002F2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","Inclusion Criteria\n\n* Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).\n* Participants must, for Arm D, have a PD-L1 expression (≥50%).\n* Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the protocol defined standard of care (SoC) treatments.\n\nExclusion Criteria\n\n* Participants must not have untreated central nervous system (CNS) metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have a history of, or any evidence of, interstitial lung disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in the radiation field is permitted.\n* Participants must not have a history of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":194,"type":195},252,"ESTIMATED","INTERVENTIONAL",[198,199],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies",[202,203,204,205],"Advanced Solid Malignancies","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)",[203,204,205,207,208,209],"Pancreatic Cancer","Lung Cancer","Kirsten rat sarcoma viral oncogene homolog (KRAS)","2026-05-26",{"date":212,"type":213},"2026-05-28","ACTUAL",{"date":215,"type":213},"2025-11-25",{"date":217,"type":195},"2028-10-13",{"name":5,"class":6},8]